Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences

Core Insights - Oculis Holding AG is set to present results from its late-stage clinical trials, including the Phase 2 ACUITY trial for Privosegtor (OCS-05) and expanded data from the Phase 3 DIAMOND program for OCS-01 eye drops, at several upcoming ophthalmology conferences [1][2][3] Company Overview - Oculis is a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases, with a late-stage clinical pipeline that includes OCS-01 for diabetic macular edema (DME) and Privosegtor for acute optic neuritis [22] Clinical Trial Highlights - The Phase 2 ACUITY trial for Privosegtor (OCS-05) demonstrated clinically meaningful visual function improvement and anatomical neuroprotection in patients with acute optic neuritis, indicating potential applications in various retinal and neurological conditions [3][19] - The Phase 3 DIAMOND program for OCS-01 eye drops aims to evaluate efficacy and safety in DME patients, with over 800 patients enrolled across two pivotal trials [18] Upcoming Presentations - Oculis will present at the Ophthalmology Futures Retina Forum and the EURETINA Congress, with specific sessions focusing on the efficacy and safety outcomes of OCS-01 in DME, highlighting its potential benefits for different patient profiles [2][9][10] Awards and Recognition - The annual Ramin Tadayoni Award, established by EURETINA in partnership with Oculis, will be announced during the EURETINA opening ceremony, recognizing outstanding postgraduate scholars in retinal disease research [4]